錦欣生殖(01951.HK)收購雲南九洲和昆明萬家部分股權
格隆匯6月18日丨錦欣生殖(01951.HK)宣佈，於2021年6月18日，公司間接全資附屬四川錦欣生殖與康芝藥業(300086.SZ)全資附屬公司廣東元寧製藥有限公司訂立股權轉讓協議，據此，四川錦欣生殖將以人民幣3774萬元收購廣東康芝醫院管理有限公司(“康芝醫院公司”)的10%股權。
據悉，康芝醫院公司是一家投資控股公司，目前於雲南九洲醫院有限公司(“九洲醫院”)及昆明和萬家婦產醫院有限公司(“和萬家醫院”，與九洲醫院統稱”該等醫院”)分別持有51%股權。
此外，同日，天津濱海遠賢管理諮詢中心(有限合夥)(“濱海遠賢”，錦欣作為LP，持有其約15%的有限合夥權益)同意以向康芝藥業的全資附屬公司及若干獨立第三方收購康芝醫院公司的90%股權及廣州雲芝彩科技有限公司(“廣州雲芝彩”)及廣州和家管理諮詢有限公司(“廣州和家”)100%股權(分別持有九洲醫院及和萬家醫院的49%股權)。
於上述交易完成後，康芝醫院公司將由公司及濱海遠賢分別擁有10%及90%；濱海遠賢將透過康芝醫院公司、廣州雲芝彩及廣州和家控制該等醫院；因此，公司將間接享有該等醫院約19.33%的經濟利益。
九洲醫院及和萬家醫院均領有體外受精(“IVF”)許可證，可為患者提供輔助生殖服務(“ARS”)，包括常規體外受精及胚胎移植(IVF-ET)以及卵細胞漿內單精子注射(ICSI)。以取卵週期數合共2,718個週期計，該等醫院於2020年合計在雲南省民營營利性IVF醫院方面排行第一。
公吿稱，收購事項屬於一項戰略投資，與集團向來遵循利用本身在中國的領導地位，通過專注收購已領有常規IVF許可證且位於對集團而言可帶來戰略優勢的地點的ARS供應商，從而擴大其ARS業務範圍的已確立戰略一致。
集團擬將其現有資源與該等醫院的資源整合，以在醫師、實驗室、臨牀管理經驗及市場營銷等方面進行合作，從而增強業務運營。因此，公司認為，該等醫院的市場份額將在不久將來顯著增加。
此外，該等醫院位於雲南省昆明，為集團帶來戰略利益，原因是收購事項將令集團的ARS網絡獲得更高的生產力及產能，並覆蓋四川、廣東、湖北及雲南等地區市場。收購事項亦為集團帶來進一步滲透至貴州以及東南亞地區的機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
